Drug Diversion Monitoring 2021
18 March 21
| Jackson Tate and Paul Warburton
Static for some time, the drug diversion monitoring market has seen a recent wave of next-generation solutions that seek to streamline the investigation process by providing consolidated, prioritized insights and more proactive alerting. However, these solutions are not all created equal. This report examines the customer experience of four next-gen vendors that have achieved broader integration and adoption—FairWarning, HelioMetrics, Invistics, and Kit Check. It also provides early insights on several next-gen solutions that are in more developmental phases (BD, Medacist, and Protenus). KLAS interviewed approximately 50% of the organizations that were live with a next-gen solution at the time this research was collected.